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Antineoplastic drugs may be neurotoxic and the clinical features frequently 
include distal sensory loss and neuropathic pain. This is related to a direct damage 
in sensory neurons and non-selective degeneration of sensory nerve fibers. Due to 
different mechanisms, there are agents that affects also motor or autonomic nerves. 
In the case of immune checkpoint inhibitors, an inflammatory response attacks the 
muscle, motor neurons or neuromuscular transmission. We present an easy-to-read 
article to understand first symptoms of chemotherapy-induced neuropathy (CIN) 
with describing each agent and the course of neuropathy as well as the clinical 
assessment with neurophysiological techniques. In addition, skin biopsy allows us to 
examine histological changes such as reinnervation. Neuroprotection with antioxi-
dant therapy is possible but more effort in this field is needed.
Keywords: chemotherapy-induced neuropathy, oxaliplatin-induced neuropathy, 
neurotoxicity, polyneuropathy, toxic neuropathy
1. Introduction
Currently the chemotherapeutic drugs are part of cancer treatment. Among 
their side effects, neurotoxicity at peripheral nervous system is a well recognize 
dose-limiting side effect. It is relevant because it causes persistent pain and sensory 
loss in cancer survivors. The prevalence of chemotherapy-induced peripheral neu-
ropathy (CIPN) has been reported around 30% of patients at 6 months after treat-
ment. It reaches up to 40% when patients are also examined with nerve conduction 
studies [1]. It is important to note that neurotoxicity could be subclinical, it means 
that it may start before patient starts to be symptomatic.
The clinical picture at presentation of CIPN is a length-dependent sensory 
polyneuropathy despite other combination of sensory, motor and autonomic nerve 
dysfunction are possible. It is important to recognize different types of sensory 
nerve fibers which are specific to different sensory modalities (touch, vibration, 
temperature and pain). All of these neurons have their cell bodies in the dorsal 
root ganglion (DRG). The thin-myelinated Aδ fibers and unmyelinated C fibers are 
known as small nerve fibers carrying thermal and painful stimulus to the brain. We 
need selective neurophysiological and histological techniques to evaluate them as 
well as to examine the function of the autonomic nervous system [2].
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SCLC = small-cell lung cancer; NSCLC: non-small cell lung cancer.
Table 1. 
Classification of commonly used chemotherapy drugs related to elevated risk of CIPN.
Figure 1. 
Different targets to produce neurotoxicity by chemotherapy.
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The most neurotoxic families of chemotherapeutic drugs are the platinum 
derivates (e.g. oxaliplatin, carboplatin or cisplatin), taxanes (e.g. paclitaxel and 
docetaxel), vinca alkaloids (e.g. vincristine), proteasome inhibitors (e.g. bortezomib) 
and immunomodulators (e.g. thalidomide and checkpoint inhibitors). Others, as 
methotrexate or arsenic salts are less frequently used. See Figure 1 a general schema 
with different targets on the peripheral nervous system and in Table 1 a list of them 
with their mechanism of neurotoxicity.
2. Acute neurotoxicity
There are drugs that can produce acute neurotoxicity, a side effect commonly 
seen with oxaliplatin. It is characterized by transient paresthesia, dysesthesia and 
muscle cramps induced by cold exposure, a phenomenon often called cold allodynia 
that typically appears during or immediately after infusion of the treatment. It 
usually resolves within a few hours or days before the next oxaliplatin cycle [3]. 
Symptoms reported by patients include tingling paresthesia in the hands (100%), 
feet (42%) and orofacial area (50%) and also, pharyngeal or laryngeal regions, all 
of them triggered by cold (especially when drinking). More infrequently, patients 
report fasciculations (29%), jaw spasms (26%), cramps (20%), difficulty of 
swallowing (18%) and neuromyotonia-like syndrome. All these phenomena reveal 
an increase in sensory and motor nerve excitability related to the impairment of 
voltage-gated sodium channels induced by oxaliplatin [4]. A functional study 
demonstrated that oxaliplatin induces reversible slowing of sodium channel inac-
tivation [5]. We know that it does not require discontinuation of treatment or dose 
reduction, but prolonging the time of infusion from 2 h to 4 or 6 h is recommended 
[6]. Some authors have found a relationship to later develop of chronic neuropathy 
[7, 8]. In particular when cold allodynia persists for days or weeks after infusion. 
Even some patients, continued to report residual symptoms in subsequent doses 
of oxaliplatin [9]. Another symptom that patients frequently ask is the Lhermitte’s 
sign, a sudden lightening sensation radiate out into both arms or feet when neck 
flexion is forced. The mechanism to produce it at cervical spinal cord is unknown 
but usually self-limited despite in some exceptional cases it could appear lately and 
be persistent during months [10, 11].
It has been described in addition acute sensitization of nociceptors with pacli-
taxel, the paclitaxel-associate acute pain syndrome. It consists of aching or other 
pain sensations mainly at lower legs peaked on day 4 after paclitaxel initiation. This 
is related to fast infusion of treatment (3 hours) but also, indicates more risk to 
sensory neuropathy after 12 weeks of therapy [12].
3. Targets of neurotoxicity at peripheral nerves
Even when all body is exposed to chemotherapy, there are tissues more vulner-
able to chemotherapy than others. This is the case of sensory neurons located at dor-
sal root ganglion (DRG) which are outside the protection of the blood–brain barrier. 
They are the principal targets of platinum derivates such us oxaliplatin, cisplatin 
or other platinum agents. Thus, neurons are damaged directly at DRG producing 
a progressive sensory neuronopathy. However, neurotoxicity also causes multiple 
lesions within the axons both for platinum agents and for other drugs as taxanes 
generating distal axonopathy. This will have different consequences for patients.
On one hand, the myelinated sensory nerve fibers lose their function. This is 
noted by many patients in a “glove and stocking” pattern of sensory loss involving 
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hands and feet. They frequently refer reduced precision to make fine movements 
with tip of the fingers which is noted by having less ability to cross buttons when 
dressing or when typing the computer. Also, gait disturbances affect their daily 
activities because of instability when walking in irregular ground or for descend-
ing stairs. On the other hand, thin myelinated (Aδ fibers) and unmyelinated 
(C fibers) carrying the information of temperature and pain are also damaged. 
A combination of negative and positive symptoms (see Figure 2) contributes 
to sensory disturbances. The unpleasant dysesthesias and neuropathic pain are 
consequence of the gain of function in damaged sensory nerve fibers that increases 
their excitability by producing spontaneous burning sensation or electric shock-
like pain.
This clinical picture is common for all chemotherapy agents despite the mecha-
nisms may differ among them. Also, it may determine the severity of axonal loss 
and its recovery since regeneration is expected to occur if the axon is affected 
distally whereas poor should be assumed in a neuronopathy. In general, we use 
the term sensory polyneuropathy for CINP when symptoms have a characteristic 
distance-dependent pattern even when we know that it is combined with sensory 
neuronopathy which has been demonstrated for oxaliplatin and cisplatin [13, 14].
There are other drugs such as vincristine, bortezomib or arsenic salts with ability 
to produce a more generalized axonal damage in all nerves. In this case, sensory 
deficits are accompanied by frequent muscular cramps, predominantly at night in 
both legs as well as distal weakness in upper and lower extremities because of motor 
neuropathy. Moreover, the failure in autonomic nerves leads to chronic constipa-
tion, reduced distal sweating and dizziness when standing (orthostatic hypoten-
sion) due to autonomic neuropathy or dysautonomia.
More recently, the introduction of the checkpoint inhibitors as a treatment for 
advance melanoma have opened the possibility of different immune-mediated 
neuromuscular manifestations reported as complication of the treatment in 75% of 
Figure 2. 
Comparison of positive and negative symptoms in CIPN.
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patients [15]. In this case acute demyelinating polyneuropathy (Guillain-Barré syn-
drome), demyelinating sensorimotor neuropathy, myositis or myasthenic syndrome 
have to be considered.
The combination of peripheral and central neurotoxicity at spinal cord should 
be considered in intrathecal infusion of chemotherapy. This is necessary for patients 
with acute leukemia treated with methotrexate. It has been described also after 
vincristine treatment. In this case, proximal motor roots can be unexpectedly block 
with a variable extension of myelitis at the level of lumbar infusion producing a 
complete paresis in lower limbs (paraparesis) with a lower abdomen level of sensory 
loss together with urinary dysfunction. This is a devastating situation that has been 
reported in few cases with poor prognosis for recovery [16, 17].
4. Risks and other conditionings for CIPN
It is difficult to establish in humans exactly the timing of changes on peripheral 
nerves after a pharmacological insult. Even though we know the day chemotherapy 
starts, there are different risk factors than makes neuropathy more probable in one 
patient than another. In Table 2 are listed the most known of them. In particular, 
one of such factors is the cumulative dose, especially for platinum agents. It was 
demonstrated that high-dose cisplatin was intrinsically more neurotoxic [23]. There 
is a range between 300 and 400 mg/m2 from which sensory symptoms starts to be 
persistent and from 540 to 850 mg/m2 from which the CIPN is generally stablished 
with high risk to be a long-term condition. However, we know now that there is no 
specific dose to be secure and probable neurotoxicity starts from first dose with a 
cumulative effect within sensory neurons.
Factors associated to higher 
risk of CIPN
Evidence Type of study Reference
Age Low Retrospective [18]
Type of cancer No evidence Observational [10]
Smoker No evidence Observational [10]
Alcoholic No evidence Observational [10]
Pre-chemotherapy neuropathy





High Retrospective vincristine [19]
Cancer-induced 
neuropathy
High Observational [10, 20–22]
Dose of chemotherapy Very High Observational
Experimental
[13, 14, 23]
Acute cold allodynia High Retrospective
Observational
[7, 8, 9]
Repeated chemotherapy Moderate Observational oxaliplatin [24]
Association with other 
chemotherapy




General risk factors for CIPN.
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One phenomenon that usually appears with platinum agents (cisplatin and 
oxaliplatin) is the coasting effect. It refers to the further progression of neuro-
toxicity during 3 to 6 months after stopping the treatment that results from its 
capacity to accumulate in DRG for a long time. It was described first for cisplatin 
[18, 27, 28] and later for oxaliplatin [9, 29, 30]. This surprises the patient who 
frequently ask worried because of deterioration of their sensory deficits after 
treatment was stopped.
5. Clinical assessment for early detection of CIPN
A good complement for clinical examination is the use of validated scales. It 
allows systematic data acquisition which is comparable in the follow-up of patients 
and also, their inclusion in research studies. There are different types of scales, ones 
are self-administered, others are based on clinical examination or they include a 
combination of clinical and results of complementary tests. We will comment two 
of the most used scales for CIPN and one self-administered scale.
The National Cancer Institute-Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) includes a scale based on the degree of impact of peripheral 
sensory neuropathy which is the most widely used scale used by oncologists [31]. 
It grades from 1 to 5 patient’s functionality disturbance due to sensory symptoms 
of neuropathy. There are different versions which are updated by the Division of 
Cancer Treatments and Diagnosis. The version 4.03 published in 2009 is currently 
the most referenced in last publications. The 5 grades are: 1) asymptomatic (weak-
ness or loss of tendon reflex on examination) or paresthesia not interfering with 
function; 2) symptomatic or sensory alterations interfering with function but 
not with daily activities; 3) weakness or sensory alterations interfering with daily 
activities; 4) life threatening disabling; 5) death.
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Only All reflexes absent
Note: Ranged from 0 to 28. CINP is significant if score > 5 points [32].
Table 3. 
TNS clinical (TNSc) scale useful for the follow-up of patients.
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The second most used scale for CIPN is the total neuropathy score (TNS). Its 
complete version was originally developed and validated for diabetic neuropathy. 
It combines clinical information obtained from grading symptoms and signs with 
neurophysiological parameters as nerve conduction studies and quantitative evalua-
tion of sensory modalities. The clinical version (TNSc) includes the first 7 items (range 
0 to 28) which are based only on clinical examination. It is showed in Table 3. A good 
correlation was reported between both, TNSc vs. NCI-CTCAE [32] even when TNSc is 
more sensitive in detecting mild sensory damage [33].
However, assessment of CIPN needs to involve subjective and objective 
information as well as the impact of the symptoms on functional activity. With 
this purpose, the European Organization for Research and Treatment of Cancer 
(EORTC) developed the self-administered scale QLQ-CIPN20. It includes 20 items 
in the form of auto-administered questions consisting of 3 scales (sensory, motor 
and autonomic). Each item range 1 (not at all) to 4 (very much) and a higher score 
is equivalent to worse or more symptoms during the past week. It should provide 
valuable information on CIPN-related symptoms and functional limitations of 
patients at risk [34].
6. Neurophysiological assessment for early detection of CIPN
There are different non-invasive techniques that provide information regarding 
the type of nerves (motor, sensory or autonomic) involved in CIPN. This is impor-
tant to confirm the diagnosis but also to identify early markers of axonal damage 
and additionally, it may help to establish the prognosis for recovery.
6.1 Nerve conduction studies (NCS)
Peripheral nerves usually can be easily stimulated by electrical stimulus and 
brought to action potential. It can be applied to sensory or motor nerves. We mea-
sure the amplitude which reflects the amount of excitable axons, and the latency of 
the response to calculate the velocity conduction. It is essential to note that both, 
latency and velocity conduction reflect only the fastest conducting fibers. On the 
other hand, low amplitude of the sensory nerve potential indicates severe axonal 
loss [35]. In Figure 3 there are examples of sensory nerve action potentials from a 
patient with sensory polyneuropathy after treatment with oxaliplatin.
The reduced amplitudes at sensory nerves with no significative changes in 
velocity conduction and motor responses are the common finding after treatment 
with platinum agents and taxanes. It affects distally sensory nerves at both sides in 
feet and hands. The sural nerve measured at ankle shows higher changes that other 
nerves such us radial or cubital nerves [36]. However, it is possible that the ampli-
tude for sural nerve will fall within normal reference values, especially after treat-
ment with oxaliplatin and taxanes in which sensory damage is limited to fingers or 
sole of the foot. The recording of the dorsal sural nerve is also recommendable to 
demonstrate low amplitudes in sensory distal polyneuropathy [37] (see Figure 3a). 
Nevertheless, not having normative values for such a distal nerve and the absence 
of response expected in the majority of the patients with CIPN makes results in 
amplitude necessary to be interpreted in relation to those obtained proximally at 
sural nerve in the same patient. If sensory symptoms are limited to hands, median 
entrapment neuropathy should be also rule out. Long-term follow up of patients 
after oxaliplatin showed persistent low amplitudes at sensory nerves 3 year after 
treatment [38].
Neurotoxicity - New Advances
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Other chemotherapy agents such us bortezomib or thalidomide produce a severe 
sensorimotor polyneuropathy with low amplitudes to all tested nerves. Despite axo-
nopathy is the most frequent finding, in some cases a demyelinating pattern with 
reduced conduction velocities and prolonged proximal motor response (F-wave) 
may be possible (i.e., for example, 3 of 26 patients reported by Chaundhry [26]). 
The presence of signs of denervation in distal muscles at lower limbs is expected on 
EMG as well as atrophy of muscles together with weakness and instability to walk 
due to sensory deficits at feet.
6.2 Quantitative sensory testing (QST)
The measurement of sensory thresholds to thermal, vibration or mechanical 
stimulus indicates the loss or gain of function to each sensory modality. Commonly, 
temperature (cold and warm) detection and pain thresholds are evaluated distally 
in the dorsum of the hands and feet. At this sites, skin thickness-dependent delay 
and attenuation of temperature is reduced for contact heating (thermode) in 
comparison to glabrous skin [39]. Through QST examination we obtain functional 
information from small and large nerve fibers depending of the sensory modality 
examined.
One of the most common findings in QST is cold allodynia, that means early 
pain sensation at low temperatures (range from 10° to 25°C) frequently seen in 
oxaliplatin treated patients. Moreover, signs of sensory loss are present early in 
CIPN at hands and feet in comparison to other proximal sites (see an example  
in Figure 3b). Patients show high thresholds for warm and cold detection as well 
as for hot pain revealing deficient function of small nerve fibers [8, 10, 40]. In 
Figure 3. 
Different techniques for diagnose CIPN. This figure shows two of the most common techniques (nerve 
conduction studies and thermotest) at evaluating the sensory function in suspected CIPN. a) the conventional 
sural nerve response, which is within normal limits (above) is compared with the more distal recording of the 
sural dorsal (below), which is clearly diminished; b) the thermode is applied at dorsum of the foot to test warm 
detection threshold (1–4 stimuli) and hot pain threshold (5–6 stimuli). Horizontal red line indicates normal 
values. The recording shows high thresholds to both, warm and pain. Note that detection of warm is near pain 
sensation because of the loss of function in C-fibers.
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addition, the higher vibration and mechanical detection thresholds at upper and 
lower limbs reported by different authors indicates the coexistence with distal 
damage at large myelinated sensory fibers [38, 41, 42]. In fact, vibration detection 
threshold at tip of the big toe was found abnormal earlier than thermal QST [43]. 
However, QST has also important limitations that should be considered. First, it 
needs patient’s cooperation. Second, a trained examiner should repeat stimuli to 
ensure consistency of responses. Finally, abnormal thresholds have been reported 
and considered a subclinical deficit for warm and cold sensations before receiving 
chemotherapy (at baseline) which makes difficult to detect a significant change 
related with starting of CIPN [10, 20, 21, 44].
6.3 Study of the autonomic nervous system
To evaluate the presence of dysautonomia, which is a failure of the sympathetic 
and/or parasympathetic nervous system, it may be possible to record the palmar 
and plantar sudomotor skin response. This is a change in the voltage measured 
from the surface of the skin which occurs after emotional or noxious stimuli, or 
following deep inspiration. The absence of response has been associated to axonal 
unmyelinated peripheral neuropathies [45]. More recently, the measurement of 
electrochemical skin conductance (Sudoscan) is an easy-use alternative that could 
have its role in future studies on CINP [46]. Parasympathetic function is assessed by 
measuring the variability of the R-R interval of heart’s beat by different maneuvers 
(normal breathing, Valsalva, stand up). It requires more complex neurophysiologi-
cal setting and the clinical relevance in CINP is still to be investigated.
7. Other non-neurophysiological techniques for early detection of CIPN
Skin biopsy allow us to examine directly under microscopy the free sensory 
nerve endings at skin. This is a well-recognize technique to quantify axonal damage 
occurring in sensory fibers with a minimal invasive punch biopsy. It provides sup-
port for diagnosing small fiber neuropathy [47] and is considered an early marker 
of more generalized (large and small) sensory polyneuropathy such us diabetic 
polyneuropathy. It makes skin biopsy presumably useful for early detection and 
monitoring patients receiving chemotherapy. Although a significant reduction in 
intraepidermal nerve fiber density has been reported by some authors after receiv-
ing oxaliplatin [42, 48], others have found cutaneous innervation more preserved 
[49]. In our experience, even when many patients show functional loss of small 
fibers (higher warm and cold detection thresholds at feet), the intraepidermal nerve 
fibers density seems to be partially preserved. Indeed, the rationale to less vulner-
ability of small neurons at DRG or higher capability to reinnervate the terminal 
small nerve fibers in contrast to myelinated receptors and fibers is still open.
Neuroimage is becoming available in different ways for providing signs of 
neurotoxicity in CIPN. Information by using these techniques is limited to few 
studies so far. Nerve high resolution ultrasound served to identify an increase in 
the cross-sectional area meaning a nerve enlargement at upper and lower limbs in 
patients receiving oxaliplatin [50] and taxanes [51]. By using magnetic resonance 
neurography has been also reported a significant hypertrophy of DRG [52] whereas 
other nerves, sciatic nerve, remain normal. In addition, changes at central nervous 
system, in dorsal columns at spinal cord, has been reported in patients affected by 
thalidomide-induced CIPN [53, 54].
Molecular biomarkers may also have a role in early detection of CIPN. They 
are in different categories, from pharmacogenomics to surrogate markers of 
Neurotoxicity - New Advances
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neurotoxicity. Unfortunately, none has been established in clinical practice because 
of lack of large-scale and validation studies. The majority of genetic variants 
which has been candidates to indicate higher susceptibility of neurotoxicity 
showed controversial results (for example, see recent reviews [55, 56]. More is 
known about other molecules reflecting nerve damage which are available at blood 
analysis such us neurofilaments. Neurofilament light chain (NfL) is a cytoskeletal 
neuron-specific protein which has found increased after receiving vincristine and 
oxaliplatin [57]. Nerve Growth Factor (NGF) levels were also find higher in painful 
CIPN whereas they remained stable in patients with painless or absent CIPN [49]. 
Other metabolic parameters such us low hemoglobin or vitamin D levels or higher 
gamma-glutamyl transferase (GGT) have been identified as independent predictors 
associated to CIPN [58].
8. When CIPN is supposed to be resolved? Indicators of recovery
This is the main question in patient’s mind which is difficult to answer. It 
depends on many factors, specially the severity of axonal loss at maximum of the 
neurotoxic effect of the drug. Complete recovery is calculated in about 40% of 
patients at 8–12 months after discontinuation of oxaliplatin whereas in almost 35% 
of patients is estimated to be persistent more than 5 years [59, 60]. Lower incidence 
has been reported for cisplatin which is estimated in 20% of patients at 12 months 
after therapy [27]. Patients treated with taxanes experience symptomatic sensory 
neuropathy distally at fingertips in hands and feet. It has been estimated in more 
than 70% of patients, being persistent in most of them longer than 5 years in some 
series [61]. Vincristine-induced neuropathy in pediatric population combines 
sensory and motor symptoms that are persistent in 27% of patients 2 years after 
treatment [62]. No correlation has been established between time until recovery 
and any clinical or neurophysiological parameter as far as I know. However, it 
is possible to said that low amplitudes at sensory nerve action potentials make 
prognosis for recovery very poor despite intraepidermal nerve fibers are partially 
preserved (personal observation).
9. Neuroprotection and other recommendations
Neuroprotectants have limited beneficial effects for preventing CIPN. The first 
step is to modify the chemotherapy regimen, such as dose reduction and longer 
interval between cycles, especially platinum agents like oxaliplatin or cisplatin and 
vincristine [63]. This is necessary in approximately 40% of patients based on aver-
age from different reports [64].
The intend to reduce oxidative-stress and the up-regulation of pro-inflam-
matory cytokines due to chemotherapy have led many authors to test antioxidant 
therapy. This is the case of vitamin B6, vitamin E and alpha-lipoic acid among 
others. Despite of contradictory results reported until now in different trials (see 
a recent review, [65]), the easiness to acquire these products for patients and their 
natural origin, most of them nutritional supplements, makes them a good choice in 
poor symptomatic CIPN or intermittent therapy between cycles of chemotherapy. 
Other pharmacological products such as the amifostine, glutathione, calcium/mag-
nesium, minocycline or mangafodipir need further research.
Symptomatic treatment with antiepileptic drugs (pregabalin, gabapentin, oxcar-
bazepine) or antidepressants (duloxetine, amitriptyline) is recommended at low dose 
with a progressive increase until partial or total alleviation of sensory symptoms.
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Regular exercise and lifestyle interventions help to prevent inactivity and 
improve body mass index [66]. Regular aerobic exercise training (30 minutes/day or 
4 hours/week) and daily walking activity between 8000 to 10000 steps/day during 
5 days/week are recommended (see https://www.foundationforpn.org). Indeed, 
they contribute to sensory and motor rehabilitation, improve self-confidence to 
walk previously diminished because of sensory loss in CIPN. Sensory feet stimula-
tion with a rubber carpet of different textures as well as hand manipulation of soft 
tissue or lentils could be a form of manual therapy for neurorehabilitation after 
receiving chemotherapy treatment. An interdisciplinary team is also recommended 
to attend needs of persons with CIPN in every oncologic center [67].
10. Conclusion
This chapter reports on clinical assessment of CIPN in such a way to be easily 
understandable. The number of cancer survivors has been fortunately growing, 
so complications of neurotoxicity after chemotherapy has become a first order 
problem for clinicians that are searching a better quality of life for their patients. 
Mechanisms to produce CIPN are diverse depending of the drug and most of them 
converge on the same targets. The present manuscript emphasizes a comparison 
of different type of nerve fibers that lead to a wide spectrum of symptoms, mainly 
sensory, which are related to axonal damage at different type of nerve fibers. 
Selective techniques are necessary to detect sensory disfunction which seems to 
affect early distal vibration and warm perception. No indicators have found to pre-
dict patient’s recovery so we have to assume that this process is possible, although 
perhaps partially, in all cases. The future will come to reduce toxic damage by per-
sonalized drug plans as well as multidisciplinary professional care to our patients.
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